Li et al. and Ma et al. found that USMB using MBs conjugated to anti-PD-L1 mAb and loaded with DTX (denoted as PDMs) or co-administered IP with cisplatin, respectively, enhanced internalization of both therapeutics, increased CD8+ T cell infiltration and inflammatory cytokine levels, and induced tumor regression in subcutaneous models of LLC lung [244] and U14 cervical cancer [245]. The gene discussed is CD8A; the disease is neoplasm.